David Scadden - Net Worth and Insider Trading
David Scadden Net Worth
The estimated net worth of David Scadden is at least $599,472 dollars as of 2024-11-10. David Scadden is the Director of Magenta Therapeutics Inc and owns about 808,674 shares of Magenta Therapeutics Inc (MGTA) stock worth over $565,748. David Scadden is also the Director of Agios Pharmaceuticals Inc and owns about 571 shares of Agios Pharmaceuticals Inc (AGIO) stock worth over $33,723. Details can be seen in David Scadden's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David Scadden has not made any transactions after 2018-06-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of David Scadden
David Scadden Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, David Scadden owns 3 companies in total, including Editas Medicine Inc (EDIT) , Magenta Therapeutics Inc (MGTA) , and Agios Pharmaceuticals Inc (AGIO) .
Click here to see the complete history of David Scadden’s form 4 insider trades.
Insider Ownership Summary of David Scadden
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| EDIT | Editas Medicine Inc | 2019-02-05 | director |
| MGTA | Magenta Therapeutics Inc | 2018-06-25 | director |
| AGIO | Agios Pharmaceuticals Inc | 2018-03-16 | director |
David Scadden Latest Holdings Summary
David Scadden currently owns a total of 2 stocks. Among these stocks, David Scadden owns 808,674 shares of Magenta Therapeutics Inc (MGTA) as of June 25, 2018, with a value of $565,748 and a weighting of 94.37%. David Scadden also owns 571 shares of Agios Pharmaceuticals Inc (AGIO) as of March 16, 2018, with a value of $33,723 and a weighting of 5.63%.
Latest Holdings of David Scadden
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| MGTA | Magenta Therapeutics Inc | 2018-06-25 | 808,674 | 0.70 | 565,748 |
| AGIO | Agios Pharmaceuticals Inc | 2018-03-16 | 571 | 59.06 | 33,723 |
Holding Weightings of David Scadden
David Scadden Form 4 Trading Tracker
According to the SEC Form 4 filings, David Scadden has made a total of 0 transactions in Magenta Therapeutics Inc (MGTA) over the past 5 years. The most-recent trade in Magenta Therapeutics Inc is the acquisition of 6,600 shares on June 25, 2018, which cost David Scadden around $99,000.
According to the SEC Form 4 filings, David Scadden has made a total of 0 transactions in Agios Pharmaceuticals Inc (AGIO) over the past 5 years. The most-recent trade in Agios Pharmaceuticals Inc is the acquisition of 200 shares on March 16, 2018, which cost David Scadden around $16,688.
Insider Trading History of David Scadden
- 1
David Scadden Trading Performance
GuruFocus tracks the stock performance after each of David Scadden's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David Scadden is -2.86%. GuruFocus also compares David Scadden's trading performance to market benchmark return within the same time period. The performance of stocks bought by David Scadden within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how David Scadden's insider trading performs compared to the benchmark.
Performance of David Scadden
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 0.88 | | | | | |
| Relative Return to S&P 500(%) | -0.15 | | | | | |
David Scadden Ownership Network
Ownership Network List of David Scadden
Ownership Network Relation of David Scadden
David Scadden Owned Company Details
What does Editas Medicine Inc do?
Who are the key executives at Editas Medicine Inc?
David Scadden is the director of Editas Medicine Inc. Other key executives at Editas Medicine Inc include SVP & CHIEF MEDICAL OFFICER Baisong Mei , director & CEO Gilmore Neil O'neill , and EVP & CHIEF SCIENTIFIC OFFICER Linda Burkly .
Editas Medicine Inc (EDIT) Insider Trades Summary
Over the past 18 months, David Scadden made no insider transaction in Editas Medicine Inc (EDIT). Other recent insider transactions involving Editas Medicine Inc (EDIT) include a net sale of 2,656 shares made by Bruce Eaton , a net sale of 32,292 shares made by Baisong Mei , and a net sale of 98,056 shares made by Gilmore Neil O'neill .
In summary, during the past 3 months, insiders sold 2,073 shares of Editas Medicine Inc (EDIT) in total and bought 0 shares, with a net sale of 2,073 shares. During the past 18 months, 168,176 shares of Editas Medicine Inc (EDIT) were sold and 45,000 shares were bought by its insiders, resulting in a net sale of 123,176 shares.
Editas Medicine Inc (EDIT)'s detailed insider trading history can be found in Insider Trading Tracker table.
Editas Medicine Inc Insider Transactions
David Scadden Mailing Address
Above is the net worth, insider trading, and ownership report for David Scadden. You might contact David Scadden via mailing address: 88 Sidney Street, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
